PolyPid (PYPD) Panoramica del titolo
PolyPid Ltd. è un'azienda biofarmaceutica che sviluppa terapie mirate, a somministrazione locale e a rilascio prolungato, utilizzando la tecnologia proprietaria della matrice di incapsulamento polimero-lipidica (PLEX) per rispondere a esigenze mediche non soddisfatte. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
PYPD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di PolyPid Ltd.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$4.84 |
| Massimo di 52 settimane | US$5.20 |
| Minimo di 52 settimane | US$2.44 |
| Beta | 1.41 |
| Variazione di 1 mese | 4.76% |
| Variazione a 3 mesi | 12.82% |
| Variazione di 1 anno | 89.80% |
| Variazione a 3 anni | -56.41% |
| Variazione a 5 anni | -98.28% |
| Variazione dall'IPO | -99.15% |
Notizie e aggiornamenti recenti
Long Regulatory And Commercial Risks Around Lead Therapy Could Eventually Reward Patient Holders
Catalysts About PolyPid PolyPid is a biopharmaceutical company developing locally and systemically delivered, long acting therapies based on its proprietary drug delivery technology, with D PLEX100 for prevention of surgical site infections as its lead program. What are the underlying business or industry changes driving this perspective?
Regulatory Tailwinds And Extended Release Platform Will Shape A Stronger Long Term Outlook
Catalysts About PolyPid PolyPid is a biopharmaceutical company focused on extended release drug delivery products such as D-PLEX100 for prevention of surgical site infections and longer acting metabolic therapies using its Kynatrix technology. What are the underlying business or industry changes driving this perspective?Recent updates
Long Regulatory And Commercial Risks Around Lead Therapy Could Eventually Reward Patient Holders
Catalysts About PolyPid PolyPid is a biopharmaceutical company developing locally and systemically delivered, long acting therapies based on its proprietary drug delivery technology, with D PLEX100 for prevention of surgical site infections as its lead program. What are the underlying business or industry changes driving this perspective?Regulatory Tailwinds And Extended Release Platform Will Shape A Stronger Long Term Outlook
Catalysts About PolyPid PolyPid is a biopharmaceutical company focused on extended release drug delivery products such as D-PLEX100 for prevention of surgical site infections and longer acting metabolic therapies using its Kynatrix technology. What are the underlying business or industry changes driving this perspective?
Long Acting Drug Delivery And Metabolic Health Pipeline Will Transform Future Prospects
Catalysts About PolyPid PolyPid is a clinical stage biopharmaceutical company focused on long acting drug delivery products such as D PLEX100 for prevention of surgical site infections and a GLP 1 receptor agonist program for metabolic disease. What are the underlying business or industry changes driving this perspective?Is PolyPid (NASDAQ:PYPD) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...PolyPid set to cut 20% jobs
PolyPid (NASDAQ:PYPD) announced on Thursday a cost reduction plan, including a 20% job cut across all departments as it expects the actions to extend tits cash runway into Q3 2023. The company expects to discuss regulatory pathway for D-PLEX100 for prevention of surgical site infections in abdominal surgery with U.S. and EU regulatory authorities in Q1 2023. As of February 28, the company had 78 full-time employees.PolyPid's surgical site infections treatment eligible for marketing nod submission in EU
PolyPid (NASDAQ:PYPD) on Wednesday said it had got confirmation from Europe's drug regulator that its D-PLEX100 product candidate for the treatment of surgical site infections was eligible to be submitted for a marketing authorization. The company said the product candidate was eligible for the European Medicines Agency's (EMA) centralized procedure under the therapeutic innovation criteria. "The centralized procedure allows the submission of a single marketing application to the EMA that, if approved, enables the product to be marketed in all EU member states as well as in Iceland, Liechtenstein and Norway," PYPD said in a statement. The company is currently evaluating its recently concluded phase 3 trial which evaluated D-PLEX100 for the prevention of surgical site infections in abdominal surgery. PYPD said it intends to discuss the data from the late-stage trial and potential next steps with U.S. and EU regulators in Q1 2023. PolyPid (PYPD) stock +1.2% to $1.10 in morning trading.PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections
PolyPid Ltd. (NASDAQ:PYPD) dropped ~75% in value in the pre-market trading Friday after the Israeli company announced that its lead candidate D-PLEX100 did not meet the main goal in a Phase 3 trial for the prevention of surgical site infections ((SSIs)) in abdominal surgery. The SHIELD I was designed to evaluate the joint administration of D-PLEX100 standard of care (SoC) against SoC alone arm in 970 patients out of whom 488 were part of the D-PLEX100 treatment arm and 489 were in the control arm. The trial did not achieve the primary endpoint of reduction in surgical site infections and mortality, the company said noting that in the Intent to Treat (ITT) population, D-PLEX100 and SoC (n=485) led to 23% decrease in SSIs and mortality compared to SoC alone (n=489) (p=0.1520).PolyPid GAAP EPS of -$1.23 misses by $0.60
PolyPid press release (NASDAQ:PYPD): Q2 GAAP EPS of -$1.23 misses by $0.60. As of June 30, 2022, the Company had cash and cash equivalents and deposits in the amount of $23.8 million, not including the second tranche of $2.5 million from the Kreos Capital VI (Expert Fund) LP (“Kreos”) loan, which was drawn in July 2022.PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
PolyPid (NASDAQ:PYPD) signed an exclusive licensing agreement for its lead drug candidate D-PLEX100 in Europe with U.K.-based Advanz Pharma (OTCPK:CXRXF). D-PLEX100 is used for preventing surgical site infections (SSIs) in abdominal and cardiac surgeries, in Europe. Under the agreement, PolyPid will receive $2.6M upfront and development-related milestones of up to $20.9M. Upon commercialization, PolyPid will receive up to $89M in sales-related milestones, the company said in an Aug. 3 press release. In addition, PolyPid will also supply D-PLEX100 to Advanz for a transfer price and will be entitled to royalties on net sales in double-digit percentages of up to mid-twenties. "Advanz Pharma's expertise in marketing hospital-based therapies, combined with its significant resources and relationships in the region, will prove invaluable in expanding access to D-PLEX100 and delivering this much-needed therapy, if approved, to patients," said PolyPid's CEO Dikla Czaczkes Akselbrad.PolyPid: Strong Pipeline, Close Catalysts
PolyPid develops a platform technology to provide locally controlled and continuous delivery of medications. Lead product candidate D-PLEX100 is investigated for the prevention of sternal and abdominal surgical site infections serving a huge market. Meaningful interim results and topline data from pivotal Phase 3 SHIELD I clinical trial will soon be published. Measured in terms of the clinical benefit of D‑PLEX100 and its estimated market size, PolyPid is clearly undervalued at present in our view.Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Rendimenti per gli azionisti
| PYPD | US Pharmaceuticals | US Mercato | |
|---|---|---|---|
| 7D | 1.7% | 2.6% | 2.5% |
| 1Y | 89.8% | 41.5% | 26.4% |
Ritorno vs Industria: PYPD ha superato il US Pharmaceuticals che ha restituito 41.5 % nell'ultimo anno.
Rendimento vs Mercato: PYPD ha superato il mercato US che ha restituito 26.4 % nell'ultimo anno.
Volatilità dei prezzi
| PYPD volatility | |
|---|---|
| PYPD Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: PYPD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di PYPD è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2008 | 72 | Dikla Czaczkes Akselbrad | www.polypid.com |
PolyPid Ltd. è un'azienda biofarmaceutica che sviluppa terapie mirate, a somministrazione locale e a rilascio prolungato, utilizzando la tecnologia proprietaria della matrice di incapsulamento polimero-lipidica (PLEX) per rispondere a esigenze mediche insoddisfatte. Il suo principale prodotto candidato è D-PLEX100, che si trova in uno studio di conferma di Fase 3 per la prevenzione delle infezioni del sito chirurgico (SSI) in pazienti sottoposti a chirurgia colorettale addominale con grandi incisioni. L'azienda sta inoltre sviluppando OncoPLEX, in fase preclinica per il trattamento del cancro intra-tumorale.
PolyPid Ltd. Riepilogo dei fondamenti
| PYPD statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$95.80m |
| Utili (TTM) | -US$33.63m |
| Ricavi(TTM) | n/a |
PYPD è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| PYPD Conto economico (TTM) | |
|---|---|
| Ricavi | US$0 |
| Costo del fatturato | US$0 |
| Profitto lordo | US$0 |
| Altre spese | US$33.63m |
| Utili | -US$33.63m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -1.76 |
| Margine lordo | 0.00% |
| Margine di profitto netto | 0.00% |
| Rapporto debito/patrimonio netto | 9.1% |
Come si è comportato PYPD nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/26 14:07 |
| Prezzo dell'azione a fine giornata | 2026/05/26 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
PolyPid Ltd. è coperta da 8 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |